Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A Plus Biotechnology CoTPE:6918 +4.07%72 5-Year Yield-on-Cost % is 7.13 as of Jul. 31, 2026, which is 149% above its 10-year median of 2.86. GuruFocus rates TPE:6918 with a GF Score™ of 72/100 and a GF Value™ of NT$87.57 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 319 Medical Devices & Instruments companies, A Plus Biotechnology Co ranks better than 83.7% on this metric.
The historical rank and industry rank for A Plus Biotechnology Co's 5-Year Yield-on-Cost % or its related term are showing as below:
TPE:6918'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.78 Med: 2.86 Max: 7.53
Current: 7.13
During the past 7 years, A Plus Biotechnology Co's highest Yield on Cost was 7.53. The lowest was 0.78. And the median was 2.86.
TPE:6918's 5-Year Yield-on-Cost % is ranked better than 83.7% of 319
companies
in the Medical Devices & Instruments industry
Industry Median: 2.45
vs TPE:6918: 7.13
A Plus Biotechnology Co (TPE:6918) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
A Plus Biotechnology Co 5-Year Yield-on-Cost % Related Terms
TPE:6918 vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, A Plus Biotechnology Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
A Plus Biotechnology Co 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, A Plus Biotechnology Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where A Plus Biotechnology Co's 5-Year Yield-on-Cost % falls into.
A Plus Biotechnology Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
A Plus Biotechnology Co (TPE:6918) has a 5-Year Yield-on-Cost % of 7.13 as of Jul. 31, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on A Plus Biotechnology Co and its competitors. This is 149% above median its historical median of 2.86. Over the past decade, A Plus Biotechnology Co's 5-Year Yield-on-Cost % has ranged from 0.78 to 7.53. According to the industry distribution chart, A Plus Biotechnology Co ranks #52 out of 319 companies in the Medical Devices & Instruments industry, placing it in the top 16.3%.
Is A Plus Biotechnology Co's 5-Year Yield-on-Cost % too high?
A Plus Biotechnology Co's current 5-Year Yield-on-Cost % of 7.13 is 149% above median its 10-year median of 2.86. Over the past 10 years, this metric has ranged from a low of 0.78 to a high of 7.53. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.45. A Plus Biotechnology Co's value of 7.13 is 191% above this industry median. Based on the distribution chart, A Plus Biotechnology Co ranks #52 out of 319 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, A Plus Biotechnology Co has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does A Plus Biotechnology Co's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, A Plus Biotechnology Co ranks #52 out of 319 companies for 5-Year Yield-on-Cost %. This places A Plus Biotechnology Co in the top 16% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.45. A Plus Biotechnology Co's value of 7.13 is 191% above this benchmark. Historically, A Plus Biotechnology Co's own 5-Year Yield-on-Cost % has ranged from 0.78 to 7.53 over the past decade. While the company's 10-year median is 2.86 vs. the industry median of 2.45, A Plus Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.45, based on 319 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. A Plus Biotechnology Co's current 5-Year Yield-on-Cost % of 7.13 is 191% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on A Plus Biotechnology Co and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. A Plus Biotechnology Co's current 5-Year Yield-on-Cost % is 7.13, which is 149% above median its own 10-year median of 2.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is A Plus Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, A Plus Biotechnology Co (TPE:6918) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.57, compared to a current price of NT$71.60 — trading 18.2% below its estimated fair value. The current 5-Year Yield-on-Cost % is 7.13, which is 149% above median its 10-year median of 2.86 and 191% above the Medical Devices & Instruments industry median of 2.45. A Plus Biotechnology Co's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For A Plus Biotechnology Co (TPE:6918), the current 5-Year Yield-on-Cost % is 7.13 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is A Plus Biotechnology Co (TPE:6918) Overvalued in 2026?
Based on GuruFocus' analysis, A Plus Biotechnology Co stock appears to be undervalued.
The current stock price of NT$71.60 is trading 18.2% below its estimated GF Value™ of NT$87.57.
GuruFocus considers A Plus Biotechnology Co to be Modestly Undervalued.
Key valuation signals for TPE:6918:
5-Year Yield-on-Cost %: 7.13 (149% above median its 10-year median of 2.86)
GF Value™: NT$87.57 vs. price of NT$71.60 (18.2% below fair value)
Industry Position: 191% above the Medical Devices & Instruments median (#52 of 319)
No single metric tells the full story. See the TPE:6918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
A Plus Biotechnology Co Ltd provides orthopedic implants and engages in the manufacturing and wholesale of medical devices such as bone material. The company's products include Chest, Shoulder, Spine, Elbow, Wrist & Hand, Pelvic & Hip, Knee, Foot & Ankle, Osteotomy, Pediatric & ESF, and Biologics. The company currently has operating segments in Taiwan and China, with the majority of revenue coming from Taiwan.
72GF Score
Get the complete analysis for TPE:6918
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6918 has been successfully added to your 
